We are live on ! Find out more
TXG icon

10x Genomics

273 hedge funds and large institutions have $1.5B invested in 10x Genomics in 2024 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 89 increasing their positions, 92 reducing their positions, and 49 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% more funds holding

Funds holding: 266 → 273 (+7)

0.3% less ownership

Funds ownership: 98.08% → 97.78% (-0.3%)

3% less repeat investments, than reductions

Existing positions increased: 89 | Existing positions reduced: 92

9% less capital inflows, than outflows

Capital inflows: $266M | Capital outflows: $293M

12% less first-time investments, than exits

New positions opened: 43 | Existing positions closed: 49

31% less call options, than puts

Call options by funds: $1.4M | Put options by funds: $2.02M

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

Holders
273
Holders Change
+7
Holders Change %
+2.63%
% of All Funds
3.58%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
43
Increased
89
Reduced
92
Closed
49
Calls
$1.4​M
Puts
$2.02​M
Net Calls
-⁠$624​K
Net Calls Change
-⁠$4.92​M

TXG Hedge Fund Activity: Q4 2024 in Review

273 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q4 2024, worth a combined $1.5B — down 36% from $2.36B a quarter earlier.

Sellers outnumbered buyers: 49 funds closed out of TXG and 43 opened new positions — a net loss of 6 holders — while 92 trimmed existing stakes and 89 added.

The largest buyer was RA Capital Management, opening a new position worth an estimated $51.8M. The largest seller was T. Rowe Price Investment Management, exiting entirely with an estimated $48.8M sold.

  • 273 institutional investors held 10x Genomics (TXG) as of Q4 2024, up from 266 in Q3 2024.
  • Funds reported $1.5B of 10x Genomics stock for Q4 2024, down 36% quarter-over-quarter.
  • 43 funds opened new 10x Genomics positions in Q4 2024 and 49 closed out, a net change of -6 holders.
  • The largest 10x Genomics buyer in Q4 2024 was RA Capital Management, an estimated $51.8M added.
  • The largest 10x Genomics seller in Q4 2024 was T. Rowe Price Investment Management, an estimated $48.8M sold.

Based on aggregated 13F filings for Q4 2024.